Navigation Links
Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
Date:4/14/2009

ced of Osprey Pharmaceutical U.S.A.'s drug candidates based on the company's proprietary platform of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders. The CCL2-CCR2 chemokine ligand-receptor axis plays a significant role in inflammatory kidney diseases such as IgA nephropathy and diabetic nephropathy, as well as a variety of other autoimmune and inflammatory conditions. CCL2-LPM is designed to target and eliminate CCR2-expressing leukocytes. In a model of glomerulonephritis, CCL2-LPM significantly decreased the influx of leukocytes into the kidney and resulted in less kidney mesangial cell proliferation and fibrosis. In preclinical testing, CCL2-LPM demonstrated no adverse effects at doses up to 1.5 mg/kg every other day for 15 doses.

About IgA Nephropathy

IgA nephropathy is the most common primary cause of kidney disease and occurs as a result of the deposition of Immunoglobulin A in the kidney. The injured kidney tissues secrete a variety of inflammatory mediators including CCL2. CCL2 in the tissue causes CCR2-expressing leukocytes to become activated and to migrate into the kidney where they perpetuate inflammation. Over time kidney function becomes compromised and over the course of 10-20 years the inflammation can lead to end-stage renal disease requiring dialysis or kidney transplant. Current treatments for IgA nephropathy include blood pressure control, diet and immunosuppressant drugs. Approximately 30 percent of IgA nephropathy patients do not respond to current therapies.

About Osprey Pharmaceuticals U.S.A.

Osprey Pharmaceuticals U.S.A. is focused on the development of protein therapeutics for the treatment of inflammatory and autoimmune conditions based on the company's proprietary therapeutic platform of Leukocyte Population Modulators (LP
'/>"/>

SOURCE Osprey Pharmaceuticals U.S.A., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
3. Strativa Pharmaceuticals Provides Product Pipeline Update
4. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
5. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
6. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
7. XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma
8. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
9. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
10. Quark Pharmaceuticals Presents at Asia TIDES Conference
11. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and LONDON , August 28, 2015 /PRNewswire/ ... approach seamlessly connects people, technologies and ... improving outcomes and the cost of healthcare ... AEX: PHIA) today announced its presence at  ESC Congress 2015 ... including Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that ...
(Date:8/27/2015)... 2015  A recent study by Feucht et ... the Arthrosurface HemiCAP® Wave implant, which is based ... design implant for isolated patellofemoral disease. While both ... pain scores, none of the patients in the ... 53% of the patients in the "onlay" group, ...
(Date:8/27/2015)... RIVERSIDE, Calif. , Aug. 27, 2015 /PRNewswire/ ... important milestone in the commercial development of the ... . The Smart Oxygen device, being developed by ... adjusts to a patient,s changing demand for oxygen ... that the 510 (k) submission for the Smart ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... 8, 2011 Reportlinker.com announces that a new ... Europe Drug Delivery Devices Market ... Europe Drug Delivery Devices Market ... GlobalData,s new report, "Europe Drug Delivery ...
... June 8, 2011 Edison Pharmaceuticals, Inc. announced ... has granted orphan drug designation to EPI-743 for ... these mitochondrial diseases affect an estimated 60,000 individuals. ... 1982, provides incentives for companies to pursue treatments ...
Cached Medicine Technology:Reportlinker Adds Europe Drug Delivery Devices Market Outlook to 2017 2Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation 2
(Date:8/29/2015)... ... August 29, 2015 , ... People who have heart or ... or asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those ... heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences ... sell Arterosil and Arterosil HP, and that all claims and counterclaims have been ... Sciences, LLC (VHS) in the United States District Court for the Southern District ...
(Date:8/28/2015)... ... August 28, 2015 , ... An online provider of CPAP machines, masks, supplies, ... CPAP equipment more affordable by offering shipping at no cost to you, directly to ... orders of any size. My Cpap Store is located in Las Vegas, Nevada. , ...
(Date:8/28/2015)... ... 28, 2015 , ... An article published August 19th by the ... gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening ... months, but the current process, having already gone on for over a year, is ...
(Date:8/28/2015)... Falls Church, VA (PRWEB) , ... ... ... and Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and ... – Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
... ventromedial prefrontal cortex may be associated with how people ... event.// ,Researchers from Massachusetts General Hospital have ... factor that affects the incidence of people developing anxiety ... , ,People who go through an intense and ...
... death was reported after being given an unauthorized Hepatitis A ... province of Anhui were administered the Hepatitis A vaccine on ... ,Li Wei a six-year-old child suffered an unspecified infection ... following which she died a few days later. Some of ...
... risk of cellular rejection after a heart transplant// ... ,The drug, a humanized monoclonal antibody, is directed ... ,Patients who were taken into the Study ... ,The primary endpoint was a composite of moderate ...
... 75 million people in the United States, Europe and Japan ... recommended that drinking calcium water may help in reducing osteoporosis., ... majority of the people do not consume enough of this ... individuals with osteoporosis but for many teenagers, and those in ...
... People who remain angry for considerable periood of time may ... ,Reserachers of University of California, Berkeley, had found that feeing ... like lowering of the immune functions, urge to pick up ... life. ,Reserachers who had done a survey of the ...
... consumption of fruits, vegetables and foods high in fibre can ... heart disease. ,Western cuisines are not so high in ... in the diet. ,10 healthy individuals were taken as ... of them. The diets were a vegetarian diet rich in ...
Cached Medicine News:Health News:Fibre Rich Food A Boon For Lowering Cholesterol 2
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... Innovators in Anesthesia and Respiratory Products, ... quality medical devices for Anesthesia and Respiratory ... manufacture products that enhance the clinician's ability ... close attention to the bottom line. , ...
... optimum lung penetration for maximum therapeutic benefit. ... µ at 6-8 LPM. Latex-free components. Usable ... the world leader in airway management products, ... proven technology by offering top brands in ...
... makeshift, modified nebulizer setups to deliver CNT ... when your patient is critical? OMNI~MAX has ... in Heliox rescue therapy. In severe obstructive ... standard of care in hospitals across the ...
Medicine Products: